Prognostic significance of hsa_circ_0048122 to predict liver metastasis in early-stage colorectal cancer.

Abstract

BackgroundLiver metastasis is the primary cause of lethal colorectal cancer (CRC). The predominant risk of poor patient prognosis in early‐stage CRC emerges as metachronous liver metastasis. This necessitates the search for potential biomarkers for this metastasis to assess treatment outcomes and provide targeted therapy.MethodsThe role of hsa_circ_0048122 in predicting liver metastasis in CRC was probed in this work. This retrospective and multi‐center investigation entailed exploration and identification stages with 158 and 176 patients. While RT‐qPCR was employed to scrutinize hsa_circ_0048122 expression, Kaplan–Meier survival, and multivariate analyses were used to probe its prognostic impact in early‐stage CRC and stage IV CRC cases, respectively.ResultsA strong correlation between liver metastases and hsa_circ_0048122 expression in stage IV CRC patients with a high hsa_circ_0048122 profile indicated a poor overall survival. Likewise, a high expression level of hsa_circ_0048122 appears as a potential predictor of liver metastases in patients' initial stages.ConclusionsPredicting liver metastasis can be plausibly facilitated using Hsa_circ_0048122 as a biomarker in early‐stage CRC cases.